经过十多年的发展,强生肿瘤业务终于迎来了属于自己的王炸时刻:2010 年,强生肿瘤的业绩只有区区 14.65 亿美元,仅占创新药收入的 6.5%;2024 年,肿瘤板块收入已狂飙至207.81 亿美元,在创新药收入中的占比达到36.4%,并首度超越自免(178.28 亿美元),成为其创新药收入的第一大来源。2025 上半年,肿瘤业务继续保持21.1% 的高速增长,创收 119.9 亿美元,是自免...
Source Link经过十多年的发展,强生肿瘤业务终于迎来了属于自己的王炸时刻:2010 年,强生肿瘤的业绩只有区区 14.65 亿美元,仅占创新药收入的 6.5%;2024 年,肿瘤板块收入已狂飙至207.81 亿美元,在创新药收入中的占比达到36.4%,并首度超越自免(178.28 亿美元),成为其创新药收入的第一大来源。2025 上半年,肿瘤业务继续保持21.1% 的高速增长,创收 119.9 亿美元,是自免...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.